Study links maropitant preservative choice to injection pain
Bottom line
A new Frontiers in Veterinary Science study suggests preservative choice may meaningfully affect how well dogs tolerate injectable maropitant. In a blinded, randomized crossover study of 32 healthy adult beagle dogs, researchers compared a benzyl alcohol–preserved formulation with an m-cresol–preserved formulation at both refrigerated and room temperatures. The benzyl alcohol formulation produced significantly lower pain scores on both visual analogue and descriptive scales, while restlessness and head shaking were reported more often with the m-cresol product. The study used Cerenia as the m-cresol comparator and a benzyl alcohol formulation supplied by ZyVet, USA. (frontiersin.org)
Why it matters: Injection pain with maropitant is a familiar clinical issue, and it’s reflected in product labeling and post-approval experience reports. The new findings reinforce earlier published work showing lower pain responses with benzyl alcohol–preserved maropitant and align with recent market activity, including Dechra’s FDA-approved Emeprev injectable, which uses benzyl alcohol as its preservative. For veterinary teams, that could influence product selection, handling protocols, and client communication when antiemetic treatment is needed in dogs and cats. (dailymed.nlm.nih.gov)
What to watch: Watch for whether these tolerability data shape purchasing decisions, label claims, or broader uptake of benzyl alcohol–preserved maropitant products in practice. (dechra-us.com)
Key facts
- Study type
- Blinded, randomized crossover study
- Sample size
- 32 healthy adult beagle dogs
- Comparison
- Benzyl alcohol-preserved maropitant vs m-cresol-preserved maropitant
- Comparator product
- Cerenia
- Benzyl alcohol source
- ZyVet, USA
- Main finding
- Benzyl alcohol formulation produced significantly lower pain scores
- Behavioral findings
- Restlessness and head shaking were more frequent with the m-cresol product
- Storage conditions
- Refrigerated and room temperature
A newly published study in Frontiers in Veterinary Science adds fresh evidence to a longstanding clinical complaint about injectable maropitant: it can sting. In a randomized, blinded crossover trial involving 32 healthy beagle dogs, investigators found that a benzyl alcohol–preserved maropitant formulation caused significantly less injection-site pain than an m-cresol–preserved formulation, regardless of whether the products were stored refrigerated or at room temperature. The m-cresol comparator was Cerenia, while the benzyl alcohol formulation was supplied by ZyVet, USA. (frontiersin.org)
That question isn’t new. Injection discomfort has been associated with maropitant for years, and it’s well recognized in clinical use and product safety information. DailyMed labeling for Emeprev notes that pain or vocalization upon injection is among reported adverse events for dogs and cats receiving maropitant citrate injectable solution, and injection-site soreness has also been documented in field experience. (dailymed.nlm.nih.gov)
The new paper also builds on earlier published evidence. A 2018 Veterinary Record Open study similarly found that a benzyl alcohol–preserved maropitant product was significantly less painful after subcutaneous injection in healthy beagle dogs than a metacresol-preserved formulation. That earlier paper pointed to benzyl alcohol’s local anesthetic properties as a plausible explanation, drawing on both veterinary and human-medicine literature. (bvajournals.onlinelibrary.wiley.com)
In the new Frontiers study, the difference was substantial. The authors reported lower visual analogue scale and simple descriptive scale pain scores with the benzyl alcohol formulation, with m-cresol increasing the odds of higher descriptive pain scores more than tenfold. They also reported excellent agreement between observers, which strengthens confidence that the effect wasn’t simply a scoring artifact. Notably, restlessness and head shaking were more frequent with the m-cresol formulation, adding behavioral support to the pain-score findings. (frontiersin.org)
Industry and clinician commentary has already been moving in the same direction. Following FDA approval of Emeprev, Dechra highlighted benzyl alcohol as a differentiating preservative and said the product was shown to be less painful on injection in healthy laboratory dogs. In separate commentary to dvm360, criticalist and internist Christopher Byers said clinicians can, when available, choose the benzyl alcohol–containing formulation to reduce injection pain, while also cautioning against mixing maropitant with subcutaneous fluids because of compatibility, stability, and absorption concerns. (dechra-us.com)
Why it matters: For veterinary professionals, this is less about whether maropitant works and more about how formulation details affect the treatment experience. Maropitant remains a widely used antiemetic in dogs and cats, especially in hospitalized patients, perioperative care, oncology, and acute vomiting cases. When the active ingredient is familiar and efficacy is expected, differences in preservative systems, injection comfort, and handling may become more important in product selection. Lower injection pain could also help reduce patient stress, make repeat dosing easier for staff, and improve the overall experience for the pet parent who sees their animal react to treatment. (dechra-us.com)
There are still limits to keep in mind. The new study was conducted in healthy beagle dogs, so real-world responses in client-owned patients, cats, or medically unstable animals may differ. And while reduced pain is clinically meaningful, it doesn’t automatically answer broader questions about cost, availability, formulary preference, or whether practices will change protocols quickly. Still, the direction of evidence is becoming harder to ignore: preservative choice appears to matter, and benzyl alcohol–preserved maropitant is gaining both published support and commercial traction. (frontiersin.org)
What to watch: The next signals to watch are whether more independent clinical data emerge in client-owned dogs and cats, whether practices shift toward benzyl alcohol–preserved options as they become more available, and whether manufacturers lean harder into tolerability as a point of differentiation in the maropitant market. (frontiersin.org)